Sanaria, malaria program to begin human trials of novel vaccine

04/23/2009 | American City Business Journals

Biotech firm Sanaria and the Path Malaria Vaccine Initiative are preparing to launch the first human trials of a vaccine that contains a weakened version of an entire malaria parasite found in radiation-zapped mosquitoes. The groups plan to enroll 104 healthy volunteers and expect to treat the first patient in mid-May.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC